Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2023-01-24 Board/Management Inform…
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 100% confidence The document announces the appointment of Frédéric Hammel as Chief Operating Officer (Directeur des Opérations) and Claire Fleury as Human Resources Director (Directrice des Ressources Humaines). This content directly relates to changes in the company's senior management team. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is a press release format, typical for such announcements, and is not a full financial report (like 10-K or IR) or a general regulatory filing (RNS).
2023-01-24 French
Inside Information / Other news releases
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of Frederic Hammel as Chief Operating Officer and Claire Fleury as Director of Human Resources. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The filing code for this is MANG. The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-01-24 English
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is a 'Bilan semestriel du Contrat de Liquidité' (Semi-annual statement of the Liquidity Contract) for Genomic Vision, detailing share and cash balances, and transaction volumes (purchases and sales) related to a liquidity agreement with CM-CIC Securities for the second half of 2022 (ending December 31, 2022). This type of disclosure, which reports on the status of a specific financial arrangement (liquidity contract/stabilization mechanism) and provides periodic transactional data, is not explicitly covered by the main financial reports (10-K, IR) or standard corporate actions (DIV, SHA, CAP). It is a specific regulatory or contractual disclosure. Since it is a periodic report detailing specific financial/contractual activity, and it doesn't fit the definitions for ER, IR, or AR, it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous, specific regulatory/contractual update, or potentially a specialized report if one existed. Given the provided definitions, RNS is the most appropriate fallback for this specific, non-standard periodic disclosure about a liquidity contract.
2023-01-13 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated January 5, 2023, announcing the successful beta testing of a new software product, FiberSmart®, by Genomic Vision. It details the product's capabilities (AI-based genomic analysis) and mentions successful testing by external parties (AstraZeneca and Fritz Lipmann Institute). This type of announcement, focusing on a specific operational or product development milestone rather than comprehensive financial results (like 10-K or ER) or management changes (MANG), is best classified as a general regulatory announcement or press release. Since it is not a formal financial report, a dividend notice, or a specific regulatory filing like DIRS or DVA, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for significant, non-standard corporate news releases.
2023-01-05 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing the successful beta testing and validation of a new software product, FiberSmart®, by Genomic Vision. It details the product's features, testing partners (AstraZeneca, Fritz Lipmann Institute), and includes quotes from the CEO and a research fellow. This type of announcement, focusing on a specific operational or product development milestone rather than comprehensive financial results (like 10-K or ER) or management changes (MANG), is typically classified as a general Regulatory Filing (RNS) or, more specifically, a news release about company operations. Since the text is a direct announcement of a business development and not a formal financial report, dividend notice, or proxy material, the most appropriate general category for non-standard announcements is RNS, as it doesn't fit the specific definitions for ER, IR, CAP, or MANG. Given the content is a news announcement, RNS is the best fit among the provided options for a non-financial, operational update.
2023-01-05 English
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing a collaboration between Genomic Vision and CNRS/CRCM regarding the use of the TeloSizer® application in cancer research to develop companion diagnostic tests. It details the scientific background, quotes key personnel, and provides standard company/contact information, concluding with a forward-looking statement. This format is typical of an initial announcement of significant business or scientific development, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a detailed management discussion (MDA). Since it is an announcement of a strategic partnership and scientific development, it does not fit perfectly into the financial reporting categories. It is best classified as a general Regulatory Filing (RNS) as it is a public announcement of material information, or potentially a general Investor Relations document, but RNS serves as the best general regulatory announcement fallback when specific categories like M&A (TAR) or Capital Change (CAP) do not apply. Given the nature of the announcement (scientific collaboration), RNS is the most appropriate general classification.
2022-11-29 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.